Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis

ConclusionOur study concluded that combination therapy with atezolizumab plus bevacizumab could increase the survival duration without affecting the disease course. Moreover, while the severity of adverse events was greater in the A  + B group, their frequency was comparable to the lenvatinib group.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research